D. Grant

Preclinical Efficacy of a PSMA-Targeted Thorium-227 Conjugate (PSMA-TTC), a Targeted Alpha Therapy for Prostate Cancer

J. Karlsson, O. von Ahsen, S. Hammer, 2019, Clinical Cancer Research.

Abstract 5857: HER2-targeted thorium-227 conjugate (HER2-TTC): Efficacy in a HER2 positive orthotopic bone model

J. Karlsson, A. Cuthbertson, D. Mumberg, 2017 .

Abstract 5859: HER2-targeted thorium-227 conjugate (HER2-TTC): Efficacy in preclinical models of trastuzumab and T-DM1 resistance

J. Karlsson, U. Wirnitzer, A. Cuthbertson, 2017 .

Expression of a high molecular weight form of insulin-like growth factor II in a Beckwith-Wiedemann syndrome associated adrenocortical adenoma.

P. Schofield, L. Spitz, A. Nystrom, 1995, Cancer letters.

Targeted alpha therapy using a novel CD70 targeted thorium-227 conjugate in in vitro and in vivo models of renal cell carcinoma

J. Karlsson, A. Cuthbertson, R. Bjerke, 2017, Oncotarget.

An efficient chelator for complexation of thorium-227.

A. Cuthbertson, T. Ramdahl, R. Bjerke, 2016, Bioorganic & medicinal chemistry letters.

Efficacy of a HER2-Targeted Thorium-227 Conjugate in a HER2-Positive Breast Cancer Bone Metastasis Model

J. Karlsson, V. Cruciani, A. Cuthbertson, 2023, Cancers.